About Vaccitech limited
Vaccitech Limited: Developing Immunotherapies and Vaccines for a Healthier World
Vaccitech Limited is a leading biotechnology company that specializes in the development of immunotherapies and vaccines. The company was founded in 2016 as a spin-out from the University of Oxford’s Jenner Institute, one of the most prestigious vaccine research centers in the world. Since its inception, Vaccitech has been at the forefront of cutting-edge research and innovation, working tirelessly to develop new treatments that can help prevent and treat some of the world's most pressing health challenges.
At Vaccitech, our mission is to improve global health by developing innovative immunotherapies and vaccines that are safe, effective, and accessible to all. We believe that everyone deserves access to life-saving treatments regardless of their location or socioeconomic status. That's why we're committed to developing affordable solutions that can be used around the world.
Our team consists of some of the brightest minds in science and medicine who are dedicated to advancing our understanding of infectious diseases such as influenza, hepatitis B virus (HBV), human papillomavirus (HPV), respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), malaria, tuberculosis (TB) among others. Our scientists have extensive experience in vaccine development using various platforms including viral vectors such as adenovirus-based vectors like ChAdOx1 which was used for COVID-19 vaccine development.
One area where we have made significant progress is in cancer immunotherapy. Our lead product candidate VTP-800 is an innovative T-cell therapy designed to target solid tumors expressing HPV16 E7 oncoprotein which causes cervical cancer among other cancers like head & neck cancer. This therapy has shown promising results so far with potential applications beyond cervical cancer treatment.
Another area where we have made significant strides is with our universal flu vaccine program which aims at developing a single flu shot that can protect against all strains of influenza virus. This is a major breakthrough in the field of flu vaccine development as current vaccines are only effective against specific strains and need to be updated every year.
At Vaccitech, we understand that developing new treatments is just one part of the equation. We also recognize the importance of ensuring that these treatments are accessible to those who need them most. That's why we work closely with governments, non-profit organizations, and other stakeholders to ensure that our products are affordable and available in low- and middle-income countries.
In conclusion, Vaccitech Limited is a world-class biotechnology company that is committed to improving global health through innovative immunotherapies and vaccines. Our team of experts has made significant progress in developing new treatments for some of the world's most pressing health challenges such as cancer, influenza, hepatitis B virus (HBV), human papillomavirus (HPV), respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), malaria, tuberculosis (TB) among others. We believe that everyone deserves access to life-saving treatments regardless of their location or socioeconomic status which drives us towards developing affordable solutions for all people around the world.